Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CARsgen Therapeutics Appoints Global Regulatory Affairs SVP | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

CARsgen Therapeutics Appoints Global Regulatory Affairs SVP

Dr. Fan will be responsible for CARsgen global regulatory strategy, leading the U.S. and China regulatory affairs team

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CARsgen Therapeutics, a clinical-stage company developing Chimeric Antigen Receptor T cell therapies for cancer, has appointed Yong Fan, MD, as senior vice president, Global Regulatory Affairs. Dr. Fan will be responsible for CARsgen global regulatory strategy, leading the U.S. and China regulatory affairs team and working with clinical, medical and process development teams to advance CARsgen’s strategic objectives for immunotherapies.

Dr. Fan previously served as A2Z Reg Solutions senior consultant and owner, member of ISCT Legal and Regulatory Affairs North America Committee, and senior reviewer in the FDA Office of Tissues and Advanced Therapies (OTAT/Previous OCTGT), Center for Biologics Evaluation and Research (CBER), responsible for review, evaluation and inspection for cellular and gene therapies’ pre-IND, IND and BLA. Prior to the FDA, she served in several roles as staff scientist at the Cell Processing Section of National Institute of Health, Laboratory Supervisor of Cellular Activities in the Gene Transfer Core Facility at the Memorial Sloan-Kettering Cancer Center, Cell Processing Lab Supervisor for New York Presbyterian Hospital-University Hospital of Columbia and Weill Cornell.

“Dr. Fan’s insights and rich experiences of regulatory strategy consulting, FDA review and regulatory inspection, cell and gene therapy research & development, and related policy implementation is a precious asset as CARsgen is developing its global strategy,” said Dr. Zonghai Li, founder and chief executive officer of CARsgen. “In the near future, CARsgen aims to submit several INDs, BLAs to U.S. FDA, China NMPA and other regulatory agencies for our advanced CAR-T cell programs. We are delighted to have Dr. Fan joined, together with more and more global top talents to deliver our commitment to cancer patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters